RhumbLine Advisers’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-47,127
| Closed | -$5.06M | – | 4397 |
|
|
2023
Q1 | $5.06M | Buy |
47,127
+3,056
| +7% | +$328K | 0.01% | 1304 |
|
|
2022
Q4 | $4.85M | Buy |
44,071
+6,035
| +16% | +$664K | 0.01% | 1293 |
|
|
2022
Q3 | $2.25M | Buy |
38,036
+4,703
| +14% | +$278K | ﹤0.01% | 1691 |
|
|
2022
Q2 | $941K | Sell |
33,333
-3,844
| -10% | -$109K | ﹤0.01% | 2169 |
|
|
2022
Q1 | $1.4M | Buy |
37,177
+1,226
| +3% | +$46.3K | ﹤0.01% | 1983 |
|
|
2021
Q4 | $1.42M | Buy |
35,951
+25,057
| +230% | +$991K | ﹤0.01% | 2059 |
|
|
2021
Q3 | $258K | Buy |
10,894
+525
| +5% | +$12.4K | ﹤0.01% | 2826 |
|
|
2021
Q2 | $255K | Buy |
+10,369
| New | +$255K | ﹤0.01% | 2853 |
|